This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!


Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

  • Tickers in this article:
  • BMY
  • AZN

Bristol-Myers Squibb's murky earnings report reveals a company still in flux.

07/24/14 - 03:30 PM EDT

Jim Cramer's Mad Dash: Gilead Sciences Still Has Upside

  • Tickers in this article:
  • GILD

TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued that shares of Gilead Sciences are not expensive given its growth rate.

07/24/14 - 11:11 AM EDT

Try Jim Cramer's Action Alerts PLUS
Cramer: Every Which Way But Short

Cramer: Every Which Way But Short

In theory, there should be plenty of shorting opportunities.

07/24/14 - 08:03 AM EDT

Ford Beats, GM Stalls, Eli Lilly Reports & Jim Cramer's Bank Pick

On a massive earnings day, Ford topped estimates on the earnings side, but disappointed on its revenue.

07/24/14 - 08:00 AM EDT

GlaxoSmithKline Cuts Full-Year Outlook as Weak Advair Sales Weigh

  • Tickers in this article:
  • GSK

Shares of GlaxoSmithKline are lower on Wednesday after the drugmaker cut its full-year earnings outlook.

07/23/14 - 12:32 PM EDT

Greenberg: Ackman and Herbalife -- The Day After

Greenberg: Ackman and Herbalife -- The Day After

  • Tickers in this article:
  • HLF

Bill Ackman's presentation failed to impress investors, but it probably should have, as Ackman raised several important points.

07/23/14 - 09:45 AM EDT

New York is Among the Top 5 Cities Searched for Pot by Leafly Visitors

Leafly is a website that helps cannabis consumers research over 800 cannabis strains and find reputable locations to purchase the right strain.

07/23/14 - 08:06 AM EDT

How Teva Pharmaceutical Is Attacking the Generics to Defend Its Turf

How Teva Pharmaceutical Is Attacking the Generics to Defend Its Turf

  • Tickers in this article:
  • TEVA

Investors are still focused on the the looming approval of generic Copaxone.

07/23/14 - 06:00 AM EDT

Don't Expect Tax Inversion Fever to Break Anytime Soon

The stream of companies undergoing inversions will continue until the U.

07/22/14 - 02:38 PM EDT

AbbVie Finally Clinches Shire Takeover Deal Valued at $55 Billion

Drugmaker AbbVie has clinched a deal worth about $55 billion to acquire British rival Shire in the biggest tax inversion deal by a U.S. company.

07/18/14 - 02:58 PM EDT

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

07/18/14 - 07:51 AM EDT

July 18 Premarket Briefing: 10 Things You Should Know

July 18 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are mixed as investors are spooked by the Malaysia Airlines jet crash in Ukraine; AbbVie succeeds in buying Shire; GE profit meets estimates.

07/18/14 - 06:41 AM EDT

Why Novartis (NVS) Stock Is Down Today

Why Novartis (NVS) Stock Is Down Today

  • Tickers in this article:
  • NVS

Novartis (NVS) shares are down after the drug company reported second quarter earnings and revenue that missed analysts expectations.

07/17/14 - 03:20 PM EDT

Buying Bluebird's Blockbuster Potential at a Discount

Buying Bluebird's Blockbuster Potential at a Discount

  • Tickers in this article:
  • BLUE

It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.

07/17/14 - 10:33 AM EDT

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs